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Abstract
Background: Benign extrinsic obstruction of the hepatic
duct, known as ‘‘Mirizzi syndrome’’ (MS), is an un-
common complication of longstanding cholelithiasis.
Since laparoscopic cholecystectomy (LC) replaced the
open approach, Mirizzi syndrome has regained the in-
terest of biliary surgeons.
Methods: The Swiss Association for Laparoscopic and
Thoracoscopic Surgery (SALTS) prospectively collected
the data on 13,023 patients undergoing LC between
1995 and 1999. This database was investigated with
special regard to patients with Mirizzi syndrome.
Results: There were 39 patients (14 men and 25 women;
mean age, 61 years) with MS (incidence, 0.3%). Thirty-
four patients had type 1 MS and ﬁve had type 2. A
gallbladder carcinoma was found in four patients (inci-
dence, 11%). In the type 1 group, 23 patients underwent
cholecystectomy only, 10 patients had a bile duct ex-
ploration and T-tube insertion, and one patient had a
Roux-en-Y reconstruction. In three patients with type 2,
a hepaticojejunostomy was performed; two others un-
derwent simple closure and drainage (via T-tube) of the
biliary ﬁstula. The conversion rate was 74% (24 of 34
patients) in the type 1 group and 100% (ﬁve of ﬁve pa-
tients) for type 2. The overall complication rate was
18%. There were no deaths.
Conclusions: Although MS is rarely encountered during
LC, it must be recognized intraoperatively. Conversion
to an open approach is often needed, and prior to any
surgical intervention, gallbladder cancer must be ex-
cluded.
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Mirizzi syndrome (MS) is a benign mechanical ob-
struction of the hepatic duct caused by an impacted
gallstone in the gallbladder neck and associated with
longstanding inﬂammatory changes of the hepatoduo-
denal ligament. The ﬁrst descriptions were published
by Ruge [24] at the beginning of the 20th century. In
1948, Mirizzi reported a ‘‘functional hepatic syndrome’’
in patients with extrinsic compression of the common
hepatic duct [18]. Although he erroneously assumed that
mechanical compression and local inﬂammation in-
duced a spasm of the hepatic duct, the clinical entity
became known as ‘‘Mirizzi syndrome’’. Cholangitis and
obstructive jaundice are the main clinical symptoms;
however, a few patients show only mild or intermitant
clinical signs due to partial obstruction.
The reported incidence of MS is low, ranging from
0.5% to 1.4%, but some ethnic populations, such as
Native Americans (Navajo and Zuni heritage), have
signiﬁcantly increased incidences as high as 2.7% [1, 4, 7].
Since a variety of local anatomical changes may occur,
several classiﬁcation systems have been developed to
assess the diﬀerent subtypes of MS [2–6, 16, 19]. The
classiﬁcation proposed by McSherry in 1982, which dif-
ferentiates between two types of MS, is currently in wide
use [16]. Type 1 is characterized by extrinsic compression
of the hepatic duct, whereas type 2 is associated with a
cholecystocholedochal ﬁstula. There is some evidence
that MS may be associated with an increased coincidence
of gallbladder cancer [20, 23]. It has been assumed that
chronic inﬂammation and cholelithiasis lead to severe
mucosal damage that is further linked to biliary cancer.
Laparoscopic cholecystectomy (LC) has almost com-
pletely replaced open cholecystectomy for the treatment
of symptomatic gallstone disease. Previous contraindica-
tions—e.g., acute cholecystitist—are no longer consid-
ered valid reasons to exclude patients from undergoing
the procedure via a laparoscopic approach. However, LC
is particularly hazardous in patients withMS because the
safe dissection of Calot’s triangle is hampered by severe
local inﬂammation and adhesions; thus, particular at-
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tention is needed to prevent bile duct injuries. Since
laparoscopic bile duct exploration and repair have not
been adopted by most laparoscopic surgeons as a stand-
ard treatment option, conversion to open bile duct
exploration is often mandatory for the patient’s safety.
The main purpose of this prospective study was to
investigate the incidence and surgical management of
MS in Switzerland in the era of laparoscopic surgery
beyond the learning curve.
Patients and methods
Since 1995, the Swiss Association for Laparoscopic and Thoracoscopic
Surgery (SALTS) has prospectively collected the data of patients un-
dergoing various laparoscopic procedures from 110 institutions in
Switzerland, with departments of general surgery (university, country,
and district hospitals) as well as from surgeons in private practice.
Approximately 7,000 laparoscopic operations are newly recorded every
year. This huge database represents 60–75% of all laparoscopic pro-
cedures performed annually in Switzerland. For every patient, more
than 130 single items, including personal records, American Society of
Anesthesiologists (ASA) classiﬁcation, indication for surgery, intra-
operative ﬁndings, operative complications, conversion rate, postop-
erative morbidity, and mortality, were recorded on a specially designed
computerized worksheet [26].
The data of 13,023 LC performed between January 1995 and
December 1999 were analyzed, and all patients withMS were identiﬁed.
Their medical records, operative reports, and an additional question-
naire, which was sent to the referring surgical institution or the general
practitioner to obtain further details and follow-up data, were then
carefully reviewed. If necessary, the institution or general practitioner
was visited by one of the investigators to collect the missing data.
There are several classiﬁcation systems of the subtypes of MS that
are in clinical use. Following McSherry’s classiﬁcation, two types of
MS were diﬀerentiated in the current study [16]. In type 1 MS, extrinsic
bile duct obstruction is caused by an impacted gallstone in either the
cystic duct or the ampulla of the gallbladder. In addition, there is a
variable degree of inﬂammation around the hepatoduodenal ligament.
Type 2 is characterized by the presence of a biliary ﬁstula between the
gallbladder and the common hepatic duct due to an ongoing de-
structive inﬂammatory reaction in the hepatoduodenal ligament.
Statistical analysis
Results are expressed as mean ± SD and range values, respectively.
Results
Characterization of patients and preoperative ﬁndings
The Swiss database included 13,023 LC for symptomatic
gallstones (78%), acute cholecystitis (15%), and other
reasons (7%). Most of the patients (90%) had a low-risk
status (ASA 1 or 2 classiﬁcation).
As shown in Table 1, only 39 patients (14 male, 25
female) with a mean age of 61 years (range, 29–90) were
found to have had MS (incidence, 0.3%). All patients
presented preoperatively with right upper quadrant pain
as the main clinical symptom; the two other symptoms
that deﬁne cholangitis—jaundice and fever—occurred in
only 21 patients (54%). One jaundiced patient under-
went LC for suspected choledocholithiasis. Thirty-four
patients (10 male, 24 female; mean age, 63.5 years) had
type 1 MS (87%); the other ﬁve (four male, one female;
mean age, 62 years) were classiﬁed as type 2 (13%).
Although the MS had been diagnosed preoperatively in
18 patients (46%), the precise type could only be con-
ﬁrmed intraoperatively. The preoperative diagnosis of
MS was made either by endoscopic retrograde cholan-
giopancreatography (ERCP) or radiological imaging
(CT scan, ultrasonography, intravenous cholangiogra-
phy) in 14 patients (41%) with type 1 and four patients
(80%) with type 2.
Four of the ﬁve patients with type 2 were jaundiced,
as were 11 of the 34 patients (32%) with type 1. The
Table 1. Patient characteristics
Overall group Patients with MS
Patients (n) 13,023 39
Age (yr)
Mean 51 61
Range 6–95 29–90
Indication (%)
Symptomatic cholecystolithiasis 10,158 (78) 21 (54)
Acute cholecystitis 1,953 (15) 17 (43)
Others 912 (7) 1 (3)
MS known preoperatively 18 (46)
MS, Mirizzi syndrome
Table 2. Characteristics, preoperative ﬁndings, and indications of
patients with Mirizzi syndrome
Type 1
(n = 34)
Type 2
(n = 5)
Patients (n) 34 5
Male/female 10/24 4/1
Age (yr)
Mean 63.5 62
Range 29–90 45–77
MS diagnosed
preoperatively, n (%) 14 (41) 4 (80)
ERCP 8 3
MRCP 1
US 2
CT 1 1
IVC 2
Clinical signs, n (%)
RUQ pain 34 (100) >5 (100)
Fever 5 (15) 1 (20)
Jaundice 11 (32) 4 (80)
Laboratory ﬁndings n (range)
Mean WBC count (·109/L) 8.8 (3.9–17.7) 11.5 (5.9–26.2)
Mean CRP (mg/L) 87 (2–386) 53 (9–100)
Mean ASAT (U/L) 71 (16–522) 149 (20–506)
Mean ALAT (U/L) 108 (12–770) 225 (13–777)
Mean AP (U/L) 154 (17–572) 482 (63–868)
Mean bilirubin (lmol/L)a 37 (4–192) 137 (12–425)
Indication
Symptomatic cholecystolithiasis 18 3
Acute cholecystitis 15 2
Obstructive jaundice 1
Emergency procedure 10 2
Elective procedure 24 3
RUQ, right upper quadrant; WBC, white blood cells (normal range,
3–5 · 109/L); CRP, C-reactive protein (normal, <3 mg/L); AST,
aspartate aminotransferase (normal, <50 U/L); ALT, alanin
aminotransferase (normal, <50 U/L); AP, alkaline phosphatase
(normal range, 30–115 U/L); ERCP, endoscopic retrograde cho-
langiopancreatography; MRCP, magnetic resonance cholangiopan-
creatography; US, ultrasonography; CT, computed tomography; IVC,
intravenous cholangiography
a Bilirubin, normal <25 lmol/L
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levels of laboratory parameters, particularly transam-
inases, alkaline phosphatase, and bilirubin, indicating
cholestasis caused by extrahepatic bile duct obstruction,
were signiﬁcantly elevated preoperatively in type 2 pa-
tients. Since acute cholecystitis occurred more frequently
in type 1 patients, their levels of C-reactive protein
(CRP) were higher than those of type 2 patients.
The diﬀerences between patients with type 1 and
those with type 2 are shown in Table 2.
Operative ﬁndings, surgical treatment, and
intraoperative complications (Table 3)
MS was already suspected preoperatively in 18 patients,
but surgical dissection of the hepatoduodenal ligament
and the gallbladder was needed to conﬁrm the precise
diagnosis and subsequently enable the diﬀerentiation
between simple external compression of the extrahepatic
biliary system (type 1) or biliobiliary ﬁstula (type 2).
Four patients with type 1 MS were simultaneously
found to have gallbladder cancer as an additional major
ﬁnding (incidence, 11.2%). An early-stage tumor was
found in two patients with dysplasia and pT1N0M0
cancer; the other two had advanced tumors (pT2N0M0
and pT3N1M0).
The overall conversion rate was 74%; conversion to
an open approach was needed in 24 of the 34 patients
with type 1 MS (71%) and all ﬁve of the patients with
type 2. In most cases, local inﬂammatory changes made
the dissection hazardous, and since laparoscopic bile
duct exploration was not done routinely, the procedure
was converted to ensure the patient’s safety.
In 23 patients with type 1, surgical intervention was
limited to cholecystectomy; another 10 patients under-
went cholecystectomy and open bile duct exploration
with T-tube insertion; a hepaticojejunostomy was per-
formed in the ﬁnal patient. All of the type 2 patients had
open bile duct exploration. Three patients underwent a
cholecystectomy and T-tube drainage; the other two
needed a hepaticojejunostomy. Complete removal of the
gallbladder was not possible in ﬁve patients (three type
1, two type 2), so only a subtotal cholecystectomy was
performed. The overall intraoperative complication rate
was 7.7%, with one bile duct injury, one duodenal lac-
eration, and one incident of local bleeding.
Postoperative morbidity, mortality, and hospital stay
(Table 4)
The overall complication rate was 10.3%. There were
two surgical complications (one bile leak, one intraab-
dominal abscess) and two systemic complications (one
upper gastrointestinal bleed, one case of pneumonia).
One patient with gallbladder cancer underwent open
reoperation, with common bile duct and liver wedge
resection, and reconstruction with a Roux-en-Y hepat-
icojejunostomy. There were no deaths.
The mean hospital stay was 12 days for type 1
(range, 4–23) and 18 days (range, 11–28) for type 2.
Discussion
The purpose of this study was to investigate the inci-
dence, preoperative diagnosis, and surgical management
of MS in the era of LC beyond the learning curve. In
addition, the coincidence of gallbladder cancer and MS
was assessed. The data from this series show that MS is
an uncommon clinical entity with an incidence of
<0.5% and that its preoperative assessment remains
diﬃcult. Conversion to an open approach is often nee-
ded so that a precise identiﬁcation of the anatomical
structures can be made and a safe repair can be com-
pleted. In contrast to other reports in the literature cit-
ing alarmingly high rates (Radaelli et al. [23]), the
incidence of simultaneous gallbladder cancer in this se-
ries was 11%.
The true incidence of MS remains unknown, because
most of the cases that are diagnosed occur in sympto-
matic patients undergoing biliary surgery, while others
may go undetected. Moreover, only case reports and
small series can be found in the literature, and there is
no diﬀerence between the open and laparoscopic era in
Table 3. Operative ﬁndings, surgical procedures, intraoperative com-
plications, and conversion rates
Type 1
(n = 34)
Type 2
(n = 5)
Operative ﬁndings
Compression of the common bile duct 34
Cholecystocholedochal ﬁstula 5
Gallbladder carcinoma (%) 4 (11.2)
Surgical procedures
Cholecystectomy 23 0
Cholecystectomy and T-tube drainage 10 3
Cholecystectomy and Roux-en-Y
reconstruction 1 2
Intraoperative complications 2 (6) 1 (20)
Bile duct injury 1
Duodenal laceration 1
Bleeding 1
Conversion rate (%) 24 (71) 5 (100)
Table 4. Postoperative complications, reinterventions, and hospital
stay
Type 1
(n = 34)
Type 2
(n = 5)
Postoperative complications (%) 3 (8.2) 1 (20)
Bile leakage 1
Intraabdominal abscess 1
Upper GI bleeding 1
Pneumonia 1
Reinterventions (%) 1 (2.9) 0
Relaparotomy 1
Relaparoscopy
Intervention (ERC, percutaneous
drainage)
Mortality 0 0
Hospital stay (d)
Mean 12 18
Range 4–23 11–28
GI, gastrointestinal; ERC, endoscopic retrograde cholangiography
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the rate of its detection [1, 2, 4, 5, 7, 8, 12, 14, 22, 25, 27–
30]. In these reports, the incidence of MS ranged from
0.4% to 2.53% [1, 2, 4, 5, 7, 12, 14, 25, 27–29].
Several classiﬁcation systems have been developed
to distinguish between diﬀerent types of MS. Involve-
ment of the hepatic duct via the destruction of its wall
or simple external compression is the most important
criterion. One of the most widely accepted and simple
classiﬁcations was proposed by McSherry, who deﬁned
type 1 as extrinsic compression of the hepatic duct and
type 2 as the presence of a cholecystocholedochal ﬁs-
tula [16]. Type 2 was further divided into several sub-
types by Csendes et al. and Nagakawa et al. based on
the extent of the destruction of the hepatic duct [6, 19].
The goal of all of these classiﬁcation systems is to en-
able the surgeon to tailor the surgical approach to the
individual case. In type 1, MS, only cholecystectomy
(total or subtotal) is needed; whereas patients with type
2 always require bile duct exploration with intraoper-
ative cholangiography, as well as extrahepatic bile duct
reconstruction via closure of the ﬁstula and T-tube
insertion, or bilioenteric anastomosis in cases with
large defects. Since the preoperative diagnosis is diﬃ-
cult to establish, and surgical experience is a critical
factor in the success of bile duct repair, the more so-
phisticated classiﬁcation systems proposed by Csendes
et al. and Nagakawa et al. probably do not provide an
signiﬁcant help to the general surgeon. If a cholecys-
tocholedochal ﬁstula is already suspected preopera-
tively the patient should be referred to a hepatobiliary
surgical center. Only meticulous dissection of the he-
patoduodenal ligament will reveal the extent of bile
duct defect and thus determine the appropriate recon-
struction technique.
Right upper quadrant pain was the most common
preoperative clinical symptom, occurring in all patients.
Whereas 80% of patients with type 2 MS were clinically
jaundiced, only one-third of patients with type 1 pre-
sented with extrahepatic bile duct obstruction. A wide
range of serum bilirubin levels was seen, and mean
values were increased signiﬁcantly only in type 2 pa-
tients. Fever occurred only rarely; therefore, neither type
1 nor type 2 was frequently associated with Charcot’s
trias, indicating cholangitis. In most series in the litera-
ture, pain was the predominant clinical symptom in all
cases; however, in contrast to this study, jaundice was
generally as frequent as pain, occurring in 60–100% of
patients [5, 7, 12, 14, 25, 29].
In addition to a routine preoperative workup in-
cluding laboratory ﬁndings and ultrasonography, ERCP
was performed in 28% of patients to further investigate
for obstructive jaundice and suspected MS. Intravenous
cholangiography, CT scan, and magnetic resonance
cholangiopancreatography (MRCP) were limited to a
few cases. Although ultrasound is the most widely used
radiological imaging technique, its predictive value for
the identiﬁcation of MS remains low [7, 10, 12]. ERCP is
actually still the most reliable modality for the investi-
gation of the extrahepatic biliary system [1, 12, 14, 29,
31]. In our series, only 40% of the type 1 MS were di-
agnosed preoperatively; the other 60% required an op-
erative exploration for ﬁnal conﬁrmation. In contrast,
four of the ﬁve type 2 cases were already known pre-
operatively due to the presence of biliary obstruction. If
the patient does not present with complete external bile
duct obstruction, as is typically seen in gallbladder
cancer, the preoperative diagnosis of type 1 MS is dif-
ﬁcult because ERCP is restricted to patients with jaun-
dice and/or elevated liver function tests. To compound
the diﬃculty, intravenous cholangiography has been
largely abandoned in the laparoscopic era.
Surgical treatment options include a broad variety of
procedures and approaches. Predominantly in type 1,
cholecystectomy and stone removal from the cystic duct
are usually performed. Due to the unclear anatomical
situation, dissection from the fundus toward Hart-
mann’s pouch and subtotal removal of the gallbladder
are advocated as a safe and eﬀective treatment option
that obviates the risk of major bile duct injury [1, 12]. In
type 2, bilioenteric anastomosis is needed in cases where
a large circumferential defect and/or cholecystocholed-
ochal ﬁstula is present. Limited common bile duct de-
fects can be closed directly with a T-tube drain. Surgical
techniques that use gallbladder ﬂaps to cover large bile
duct defects have been shown to be associated with an
increased complication rate and have therefore been
abandoned [1, 11, 31]. Finally, a laparoscopic procedure
is usually attempted, but conversion to an open ap-
proach is favored by most experienced surgeons [8, 11,
12, 30].
Gallbladder cancer is a rare disease in Western
countries that is strongly associated with longstanding
cholelithiasis and chronic cholecystitis [9, 15]. Although
MS and gallbladder cancer have similar risk factors as
mentioned previously (long-standing cholelithiasis,
chronic cholecystitis), there are only a few reports de-
scribing the coincidence of gallbladder cancer in patients
with MS [17, 21, 23]. Whereas Redaelli et al. reported an
alarming coincidence of 28%, the rate of cancer in our
series was 11% [23]. A strong association between MS
and gallbladder cancer can therefore be assumed. For
the reason, frozen sections should be obtained from all
patients undergoing surgery for MS. Since the prognosis
of patients with gallbladder cancer is dismal, an accurate
diagnosis followed by radical open surgical treatment
provides their best hope.
The postoperative morbidity and mortality rates
were <10% and zero, respectively, and most complica-
tions were minor (e.g., bile leakage). The fact that the
surgical treatment of MS can be performed safely is also
conﬁrmed by most of the reports in the literature, with
few complications and nearly no deaths [2, 5, 7, 11, 12,
28, 29].
In conclusion, MS is a rare complication of long-
standing cholelithiasis with a low incidence; however,
laparoscopic surgeons must be wary. The preoperative
diagnosis is not of utmost importance, but its intraop-
erative recognition and a low threshold for conversion
to open bile duct exploration are crucial to the long-
term outcome. Because there is strong evidence that the
incidence of simultaneous gallbladder cancer is signiﬁ-
cantly increased, frozen sections must be obtained to
exclude the presence of local malignancy prior to closure
or bile duct reconstruction.
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